[Conservative treatment of benign prostatic hyperplasia (author's transl)].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D003534:Cyproterone / Q000627:therapeutic use; D005866:Gestonorone Caproate / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008524:Medrogestone / Q000627:therapeutic use; D008535:Megestrol / Q000627:therapeutic use; D010936:Plant Extracts / Q000627:therapeutic use; D011090:Polyenes / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013148:Spironolactone / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D010936:Plant Extracts; D011090:Polyenes; D008524:Medrogestone; D013629:Tamoxifen; D013148:Spironolactone; D001971:Bromocriptine; D003534:Cyproterone; D008535:Megestrol; D005866:Gestonorone Caproate
Konservative Therapie der benignen Prostatahyperplasie (bph).